CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 400 target
Drug / intervention
ENCODEother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06342401
NCT06342401N/ARecruitingOn TrackUpdated 5mo ago
Long Recruiting

Development and Validation fo an Exosome-Based and Machine Learning Powered Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer

City of Hope Medical Center·observational·Posted Apr 2, 2024·Updated Jan 28, 2026

In Brief

An observational study evaluating ENCODE for Colorectal Cancer and 7 related conditions. Currently recruiting, targeting 400 participants across 13 sites in 4 countries.

Detailed Summary

Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women. This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly, Japan, Spain, United States
Collaborators--

Timeline

N/ARecruitingOverdue
202420252026
First PostedApr 2, 2024
Enrollment StartApr 15, 2023
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 2.2 years ago

Interventions

ENCODEother

A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.